In conclusion, the neoadjuvant chemotherapy regimen of trastuzumab combined with docetaxel and carboplatin exhibited significant efficacy, tolerable adverse reactions and a high pCR rate in the HER-2-overexpressing breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.